research Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Alopecia Areata: Genetic and Immunological Insights
Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.
research Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 NKG2D Lymphocytes in Alopecia Areata Patients
EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.
research Observation and Consideration on Using of JAKi in Clinical Trials in Times of COVID-19
Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
research Molecular Basis of Hair Follicle Donor Dominance in Androgenetic Alopecia and Sexual Dimorphism of the Skin
Hair loss patterns differ between males and females due to 5 master regulators and JAK-STAT signaling affects hair growth.
research The Changing Landscape of Alopecia Areata: The Translational Landscape
New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.
research Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
research NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications
NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
research Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: Evidence to Date
Baricitinib is a promising treatment for alopecia areata.
research Frontal Fibrosing Alopecia Shows Robust T Helper 1 and Janus Kinase 3 Skewing
Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.
research Predictive Modeling of Drug Response and Mechanism of Action in Alopecia Areata Clinical Trials
Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.
research The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies
Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
research Emerging Drugs for Alopecia Areata: JAK Inhibitors
JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
research The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Screening for Latent Infectious Disease in Patients with Alopecia Areata Before Initiating JAK Inhibitors Therapy: A Single-Center Real-World Retrospective Study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
research Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
research JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Janus Kinase Inhibitors in Dermatology: A Systematic Review
JAK inhibitors help with skin conditions but need more research on dosing and safety.
research Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Safety of Janus Kinase Inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
Baricitinib reduces inflammation and improves cell health in premature aging cells.
research A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
research Mesenchymal Stem Cells Antagonize IFN-Induced Proinflammatory Changes and Growth Inhibition Effects via Wnt/β-Catenin and JAK/STAT Pathway in Human Outer Root Sheath Cells and Hair Follicles
Mesenchymal stem cells may help treat hair loss by improving hair cell growth and reducing inflammation.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.